Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity

Simply Wall St.03-30

Earlier in March 2026, the European Medicines Agency’s CHMP issued a positive opinion to expand Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) label to treat obesity and control hunger in adults and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623392534?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-30 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623392534","market":"hk","top_or_hot":-1,"title":"Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity","media":"Simply Wall St.","content":"<div>\n<p>Earlier in March 2026, the European Medicines Agency’s CHMP issued a positive opinion to expand Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) label to treat obesity and control hunger in adults and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-is-down-133-after-ema-backs-imci\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Pharmaceuticals (RYTM) Is Down 13.3% After EMA Backs IMCIVREE Label Expansion for Hypothalamic Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 14:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-is-down-133-after-ema-backs-imci><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in March 2026, the European Medicines Agency’s CHMP issued a positive opinion to expand Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) label to treat obesity and control hunger in adults and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-is-down-133-after-ema-backs-imci\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-is-down-133-after-ema-backs-imci","article_id":"2623392534","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/rhythm-pharmaceuticals-rytm-is-down-133-after-ema-backs-imci","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623392534","pubTimestamp":1774851009,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in March 2026, the European Medicines Agency’s CHMP issued a positive opinion to expand Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) label to treat obesity and control hunger in adults and children 4 years and older with acquired hypothalamic obesity due to hypothalamic injury or impairment, adding to the drug’s existing rare obesity indications.\nThis European regulatory milestone, coming shortly after U.S. approval for acquired hypothalamic obesity, reinforces Rhythm’s focus on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","AI":"C3.ai, Inc.","BK4139":"生物科技","AIPO":"Defiance AI and Power Infrastructure ETF","BK4528":"SaaS概念","BK4585":"ETF&股票定投概念","BK4543":"AI","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AGIX":"通用人工智能 ETF-AGIX","BK4551":"寇图资本持仓","BK4081":"电力公用事业","EMA":"Emera Inc.","BK4587":"ChatGPT概念","RYTM":"Rhythm Pharmaceuticals Inc.","BK4588":"碎股","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF"},"translate_title":"EMA支持IMCIVREE扩大治疗下丘脑肥胖症的标签后，Rhythm Pharmaceuticals(RYTM)股价下跌13.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EMA":1.5,"AIPO":0.62,"AIYY":0.6,"AI":0.62,"CHAT":0.62,"RYTM":1.5,"AGIX":0.62},"content_text":"Earlier in March 2026, the European Medicines Agency’s CHMP issued a positive opinion to expand Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide) label to treat obesity and control hunger in adults and children 4 years and older with acquired hypothalamic obesity due to hypothalamic injury or impairment, adding to the drug’s existing rare obesity indications. This European regulatory milestone, coming shortly after U.S. approval for acquired hypothalamic obesity, reinforces Rhythm’s focus on MC4R-pathway rare obesity disorders and broadens the addressable patient pool across both regions. We’ll now examine how the CHMP’s supportive stance on acquired hypothalamic obesity could reshape Rhythm’s investment narrative and long-term outlook. The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementRhythm Pharmaceuticals Investment Narrative RecapTo own Rhythm, you need to believe IMCIVREE can sustain and expand its rare‑obesity franchise fast enough to offset ongoing losses and high R&D spend. The CHMP’s positive opinion for acquired hypothalamic obesity supports that thesis, but does not remove the near term risk of continued operating losses and potential future equity dilution after the recent US$200,000,000 at the market filing. The FDA’s March 2026 approval of IMCIVREE for acquired hypothalamic obesity in patients 4 years and older is the most relevant backdrop here, since the CHMP opinion effectively mirrors that label expansion in Europe and highlights how much Rhythm’s story depends on this single asset and its evolving safety and reimbursement profile. Yet against this wider opportunity, investors should be aware that Rhythm still relies heavily on a single drug and... Read the full narrative on Rhythm Pharmaceuticals (it's free!)Rhythm Pharmaceuticals’ narrative projects $898.7 million revenue and $244.2 million earnings by 2029.Uncover how Rhythm Pharmaceuticals' forecasts yield a $135.53 fair value, a 79% upside to its current price.Exploring Other PerspectivesRYTM 1-Year Stock Price Chart Four members of the Simply Wall St Community currently estimate Rhythm’s fair value between US$33.51 and US$431.23, underlining how far opinions can differ. Against that wide range, Rhythm’s continued operating losses and recent US$200,000,000 at the market offering raise important questions about how you think about funding risk and future execution.Explore 4 other fair value estimates on Rhythm Pharmaceuticals - why the stock might be worth over 5x more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Rhythm Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rhythm Pharmaceuticals' overall financial health at a glance.No Opportunity In Rhythm Pharmaceuticals?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623392534","isCrawlerRequest":true}